How Sponsors and Sites Work Together to Improve Protocol Compliance
Sites and sponsors can adopt strategies to reduce quality issues and avoid FDA warning letters by improving collaboration, training, and resource access.
Sites and sponsors can adopt strategies to reduce quality issues and avoid FDA warning letters by improving collaboration, training, and resource access.
Staff turnover in clinical research impacts trial quality and timelines. Addressing this requires focus on workplace culture, career growth, and competitive benefits.
OnCore’s future vision focuses on cloud-hosted solutions, cross-platform reporting, and SSO, enhancing efficiency and user experience for research sites.
Ensuring the safe and secure transport of investigational products (IP) is a core part of biosafety. This critical task requires
The clinical trial startup process has seen significant shifts over the past five years: growth in decentralized trials, improved technology,
Research sites play a pivotal role in clinical trials, responsible for participant recruitment, data collection, safety monitoring, regulatory management, overall
HRPP staffing is essential for maintaining research ethics, even with sIRB mandates streamlining review processes for multisite studies. Discover key HRPP roles and benefits.
GxP guidelines help clinical research meet rigorous standards for safety, quality, and compliance, supporting the development of therapies and medical devices.
Human research protection programs (HRPPs) play a critical role in protecting the rights, safety, and welfare of research participants. A
As research institutions are designing studies and recruiting participants for them, they must maintain compliance and ensure their study is
Single IRB (sIRB) review streamlines oversight for multisite trials, reducing administrative burdens while ensuring participant protections across all sites.
Gene therapy research is at the forefront of a coming boom in the clinical setting. Understand the growth, risks, and regulatory requirements here.